Early Invasive Versus Conservative Therapy in Women With an Acute Coronary Syndrome

This study aims to enroll 1,000 women who present with AcuteCoronarySyndorme ( ACS). Patients will be identified through screening of all women admitted for chest pain, and those women with positive cardiac enzymes after operative procedures. After receiving permission to approach the potential subjects, trained and delegated study personnel will present the study to the patient. The informed consent process will be completed by the study coordinator, PI or co-investigator. The patient will have all procedures, risks and benefits explained and offered time to read and review the informed consent form. They will be given adequate time to ask questions, consult with family members or primary physicians. Specifically, written informed consent will be obtained in the emergency department or in the cardiology ward/unit before the patient is sedated/in the catheterization laboratory. . When a patient consents to participate in the study, their treatment assignment will be randomly determined by opening a sealed envelope that contains one of two treatment strategies. The blinding envelopes will be created by the Biostatistics group and will be sealed.

Once informed written consent is obtained (see accompanying flow chart), each patient will be randomly assigned to early invasive therapy versus conservative management. All patients will be administered aspirin 325 mg, clopidogrel 600 mg, and atorvastatin 80 mg. Anti-thrombin therapy (unfractionated heparin or bivalirudin according to physician discretion) will be administered intravenously. If anti-thrombin therapy was administered prior to randomization, this agent will be continued through catheterization and titrated if necessary to achieve desired effect.

Patients assigned to an early invasive strategy will undergo coronary angiography within 48 hours and have percutaneous coronary intervention or coronary artery bypass grafting performed as soon as possible during the initial hospitalization if deemed appropriate. The choice of intervention or surgery will be determined by the operator according to coronary anatomy and consistent with current practice guidelines. For example, disease of the left main trunk, or multi-vessel disease would generally be expected to be referred for surgical revascularization. Patients who undergo percutaneous coronary intervention can receive a glycoprotein IIb/IIIa inhibitor (i.e. abciximab bolus by intra-coronary or intra-venous route (0.25 mg per kg), followed by infusion (0.125 µg per kg per minute for 12 hours). Upfront use of glycoprotein IIb/IIIa inhibitors is discouraged. Eptifibatide or tirofiban can be used instead of abciximab according to operator discretion. Elective percutaneous coronary intervention on non-culprit vessels, in either study arm, can take place sometime after the index procedure with the goal to achieve complete revascularization. Such staged procedures will not be adjudicated as an urgent need for revascularization.

Patients assigned to conservative management will be treated with anti-anginal medications, as well as aspirin, clopidogrel, atorvastatin, and other guideline recommended medicines. Anti-thrombin therapy will be continued for no more than 48 hours. Conservative therapy will continue during this time, unless the patient has refractory angina, hemodynamic or electrical instability, left ventricular dysfunction (left ventricular ejection fraction < 45%), or significant ischemia on predischarge stress testing. Patients will have an echocardiogram to determine left ventricle function. Stress testing will be performed by adenosine SPECT if there is no left ventricular dysfunction by echocardiography. Patients with any high risk findings, such as refractory chest pain, left ventricular ejection fraction < 45%, or a large burden of ischemia on stress testing will remain in the hospital to undergo cardiac catheterization.

Patients in both groups will be treated with lifelong aspirin, 12 months of clopidogrel, in addition to atorvastatin and other guideline recommended therapies. A shorter duration of clopidogrel can be recommended in select cases according to treating physician discretion.

Specific data for acquisition:

Protected health information will be accessed by the practitioners normally involved in the patient's care during their hospitalization. Research demographics will be obtained by the research coordinator by interviewing the patient and by chart review. After hospital discharge, the research coordinator will contact the patient at specified intervals to determine if an endpoint has been met. Evidence that an endpoint occurred would require additional supplemental chart review by the research coordinator.

Patient demographics: age, height, weight, body mass index, medications at randomization, pertinent medical/surgical/family/social history: for example hypertension, hypercholesterolemia, diabetes mellitus, current tobacco use, history of: prior myocardial infarction, percutaneous coronary intervention or coronary artery bypass grafting. This data will be gathered by the research coordinator through patient reporting and chart review.

Procedural: Duration of ischemic symptoms from onset until randomization, electrocardiographic changes, elevated cardiac biomarkers, elevated NT-pro-BNP, procedural success defined as Thrombolysis In Myocardial Infarction flow 3, drug-eluting stent use, glycoprotein IIb/IIIa inhibitor use, intra-procedural activated clotting time, closure device, sheath size, micropuncture access.